Objectives: To determine the susceptibilities of M.hominis and U. urealyticum to fluoroquinolones forthe instruction of reasonable clinical application ofantibiotics.Method: The susceptibilities of M. hominis and U.ur...Objectives: To determine the susceptibilities of M.hominis and U. urealyticum to fluoroquinolones forthe instruction of reasonable clinical application ofantibiotics.Method: The susceptibilities of M. hominis and U.urealyticum to six fluoroquinolones were determinedby the broth dilution method.Results: Sparfloxacin and gatifloxacin were veryactive with MIC50S of 0.03125 and 0.25 μg/ml againstM. hominis, 0.25 and 0.5 μg/ml against U. urealyticum,respectively. Levofloxacin and ofloxacin had MIC50S of1 μg/ml and 2 μg/ml, respectively against both species.Norfloxacin was less effective against both species at16 and 32 μg/ml. Ciprofloxacin was unusual in thatthe MIC50S varied fourfold between species, with 2 μg/ml against M. hominis and 8 μg/ml against U.urealyticum.Conclusions: The results can provide useful infor-mation for selecting fluoroquinolones for treatmentof urogenital mycoplasma infections.展开更多
基金Financially supported by a grant from the Education Com-mittee of Hunan Province (No.ooAoo9)
文摘Objectives: To determine the susceptibilities of M.hominis and U. urealyticum to fluoroquinolones forthe instruction of reasonable clinical application ofantibiotics.Method: The susceptibilities of M. hominis and U.urealyticum to six fluoroquinolones were determinedby the broth dilution method.Results: Sparfloxacin and gatifloxacin were veryactive with MIC50S of 0.03125 and 0.25 μg/ml againstM. hominis, 0.25 and 0.5 μg/ml against U. urealyticum,respectively. Levofloxacin and ofloxacin had MIC50S of1 μg/ml and 2 μg/ml, respectively against both species.Norfloxacin was less effective against both species at16 and 32 μg/ml. Ciprofloxacin was unusual in thatthe MIC50S varied fourfold between species, with 2 μg/ml against M. hominis and 8 μg/ml against U.urealyticum.Conclusions: The results can provide useful infor-mation for selecting fluoroquinolones for treatmentof urogenital mycoplasma infections.